Literature DB >> 19636337

Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese.

Q Zhou1, X M Yu, H B Lin, L Wang, Q Z Yun, S N Hu, D-M Wang.   

Abstract

The cytochrome P450 2C19 and 2D6 enzymes are predominantly found in the human liver, and have important functions in the metabolism of many different classes of commonly used drugs. Their genetic polymorphisms give rise to both important interethnic variability in metabolism and the risk of treatment failure or dose-dependent drug toxicity. To investigate genetic polymorphisms in CYP2C19 and CYP2D6 genes in Han Chinese, we sequenced regions of the 5' flanking region, exon, intron and 3' UTR from these two genes using 100 unrelated healthy Chinese Hans. We detected 48 genetic variants in CYP2C19. A total of 15 of them are novel, including two polymorphisms in putative transcriptional factor-binding sites. The CYP2C19*1, *2, *3, *4, *17, *23, *24 and *25 alleles have frequencies of 67.5, 25.5, 2, 0.5, 3, 0.5, 0.5 and 0.5%, respectively. Based on computational predictions, three novel alleles (CYP2C19*23, *24 and *25) are deleterious mutations of the CYP2C19 protein. In CYP2D6, we identified 84 different polymorphisms, including 18 novel single-nucleotide polymorphisms. One novel polymorphism is located in a potential cis-regulatory element of the gene. The allele frequencies of CYP2D6*1, *2, *4, *5, *6, *10, *14, *21, *36, *41, *43, *52 and *71 are 18.5, 14, 1, 7, 0.5, 49, 1.5, 0.5, 1, 4, 0.5, 1 and 1.5%, respectively. The occurrence of CYP2D6 duplication is 0.5%. The novel CYP2D6*71 is anticipated as a putative poor metabolizer allele. We also performed linkage disequilibrium analysis and observed strong linkage disequilibrium spanning of the CYP2C19 and CYP2D6 regions. In addition, network analysis showed that 15 haplotypes of CYP2C19 and 22 of CYP2D6 are classified into five and three groups, respectively. Comparisons of allele frequency distributions revealed significant interethnic and intraethnic differences in these two genes. In conclusion, this study revealed that CYP2C19 and CYP2D6 have a complicated allele composition and distinct frequency distribution in Han Chinese.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19636337     DOI: 10.1038/tpj.2009.31

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  23 in total

Review 1.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

2.  Genetic polymorphisms and phenotypic analysis of drug-metabolizing enzyme CYP2C19 in a Li Chinese population.

Authors:  Yipeng Ding; Dongchuan Xu; Xiyang Zhang; Hua Yang; Tingting Geng; Ping He; Jinjian Yao; Shengyang Yi; Heping Xu; Duoyi Wu; Xiang Wang; Tianbo Jin
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

3.  Genetic polymorphisms of metabolic enzymes and the pharmacokinetics of indapamide in Taiwanese subjects.

Authors:  Teng-Hsu Wang; Cheng-Huei Hsiong; Hsin-Tien Ho; Tung-Yuan Shih; San-Jan Yen; Hui-Hung Wang; Jer-Yuarn Wu; Benjamin Pei-Chung Kuo; Yuan-Tsong Chen; Shung-Tai Ho; Oliver Yoa-Pu Hu
Journal:  AAPS J       Date:  2013-12-20       Impact factor: 4.009

4.  Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness.

Authors:  S A Scott; S Martis; I Peter; Y Kasai; R Kornreich; R J Desnick
Journal:  Pharmacogenomics J       Date:  2011-03-01       Impact factor: 3.550

5.  CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects.

Authors:  Sze Wa Chan; Miao Hu; Sara Shun Wah Ko; Catherine Wing Yan Tam; Benny Siu Pong Fok; Ophelia Qi Ping Yin; Moses Sing Sum Chow; Brian Tomlinson
Journal:  Eur J Clin Pharmacol       Date:  2012-10-23       Impact factor: 2.953

6.  Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort.

Authors:  Sheng-Chang Wang; Ing-Kang Ho; Hsiao-Hui Tsou; Sheng-Wen Liu; Chin-Fu Hsiao; Chia-Hui Chen; Happy Kuy-Lok Tan; Linen Lin; Chi-Shin Wu; Lien-Wen Su; Chieh-Liang Huang; Yi-Hong Yang; Ming-Lun Liu; Keh-Ming Lin; Shu Chih Liu; Hsiao-Yu Wu; Hsiang-Wei Kuo; Andrew C H Chen; Yao-Sheng Chang; Yu-Li Liu
Journal:  OMICS       Date:  2013-09-09

7.  Functional characterization of 21 CYP2C19 allelic variants for clopidogrel 2-oxidation.

Authors:  M Takahashi; T Saito; M Ito; C Tsukada; Y Katono; H Hosono; M Maekawa; M Shimada; N Mano; A Oda; N Hirasawa; M Hiratsuka
Journal:  Pharmacogenomics J       Date:  2014-07-08       Impact factor: 3.550

8.  Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition.

Authors:  Amelia Nathania Dong; Nafees Ahemad; Yan Pan; Uma Devi Palanisamy; Beow Chin Yiap; Chin Eng Ong
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-04-26       Impact factor: 3.000

9.  Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients.

Authors:  Joanne Siok Liu Lim; Natalia Sutiman; Thomas E Muerdter; Onkar Singh; Yin Bun Cheung; Raymond Chee Hui Ng; Yoon Sim Yap; Nan Soon Wong; Peter Cher Siang Ang; Rebecca Dent; Werner Schroth; Matthias Schwab; Balram Chowbay
Journal:  Br J Clin Pharmacol       Date:  2016-03-08       Impact factor: 4.335

10.  CYP2D6*3 (A2549del), *4 (G1846A), *10 (C100T) and *17 (C1023T) genetic polymorphisms in Iranian breast cancer patients treated with adjuvant tamoxifen.

Authors:  Fatemeh Saghafi; Ebrahim Salehifar; Ghasem Janbabai; Ehsan Zaboli; Akbar Hedayatizadeh-Omran; Omolbanin Amjadi; Siavash Moradi
Journal:  Biomed Rep       Date:  2018-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.